Bangladesh NTP 2021: tuberculosis
Bangladesh national National Tuberculosis Control Programme (NTP), DGHS Current
National Guideline and Operational Manual for Tuberculosis, 6th edition
National Tuberculosis Control Programme, DGHS, Bangladesh. October 2021
Summary checked against the source: 2026-11
Not published online. Ask NTP, DGHS, or see the local PDF TB_BD-NTP_2021_Guideline-6thEd.pdf
Page numbers in brackets are the guideline's own printed page numbers.
At a glance
- Presumptive TB: cough ≥2 weeks despite a broad-spectrum antibiotic. Any cough at all in contacts, PLHIV and people with extra-pulmonary TB. [p. 13–14]
- GeneXpert (Xpert MTB/RIF) is the first test wherever it's available. Smear microscopy is being phased out. [p. 16, 18]
- No trial of TB treatment. Treat only bacteriologically confirmed or clinically diagnosed TB. [p. 11]
- New patients, pulmonary or extra-pulmonary: 2HRZE / 4HR, daily, as fixed-dose combinations by weight band. [p. 27–29]
- TB meningitis and bone or spinal TB: 12 months. Steroids for meningitis and pericarditis. [p. 31]
- Previously treated: test for drug resistance first. H and R sensitive: 2HRZE/4HR. Rifampicin-sensitive but isoniazid-resistant or unknown: 6(H)REZ-Lfx. [p. 27–28]
- MDR/RR-TB: shorter all-oral bedaquiline regimen (9–11 months) if eligible; otherwise the longer 18–20 month regimen. [p. 49–50]
- TB preventive treatment for PLHIV and household contacts: 3HP, 3RH or 6H. [p. 62]
Definitions and classification
| Term | Definition |
|---|---|
| Bacteriologically confirmed | Positive smear (LED or ZN), culture, or a WHO-recommended rapid test such as Xpert MTB/RIF, Ultra or TrueNat |
| Clinically diagnosed | Not bacteriologically confirmed, but a registered physician decides to give a full course on clinical, X-ray or histological evidence |
| Pulmonary | Lung parenchyma or tracheobronchial tree. Miliary TB counts as pulmonary. Pulmonary plus extra-pulmonary counts as pulmonary |
| Extra-pulmonary | Other organs. Intrathoracic lymphadenopathy or pleural effusion without lung lesions is extra-pulmonary |
| New | Never treated, or treated for less than 1 month |
| Previously treated | 1 month or more of anti-TB drugs in the past: relapse, after failure, after loss to follow-up, or other |
Adapted from BD-NTP 2021 sections 3.1–3.2 [p. 11–13]
Drug resistance
| Term | Resistance to |
|---|---|
| Mono-resistance | One first-line drug |
| Poly-resistance | More than one first-line drug, but not both H and R |
| Hr-TB | Isoniazid, with rifampicin susceptibility confirmed |
| RR-TB | Rifampicin (by phenotypic or genotypic test) |
| MDR-TB | At least isoniazid and rifampicin |
| Pre-XDR (MDR with quinolone resistance) | MDR plus levofloxacin or moxifloxacin |
| XDR-TB | MDR plus a fluoroquinolone plus bedaquiline or linezolid |
Adapted from BD-NTP 2021 section 9.1 [p. 47]
Diagnosis
flowchart TD
A["Presumptive TB"] --> M["Microscopy site"]
A --> X["GeneXpert site"]
M --> SN["Smear negative"]
M --> SP["Smear positive<br/>(test by GeneXpert if available,<br/>or enrol for treatment)"]
SN --> CE1["Further clinical evaluation by physician<br/>e.g. CXR, GeneXpert if highly suggestive"]
SP --> F1["First-line drugs"]
SP --> G["GeneXpert test"]
X --> G
G --> N["MTB not detected"]
G --> D["MTB detected,<br/>RR not detected"]
G --> R["MTB detected,<br/>RR detected"]
G --> E["Error / invalid / no result /<br/>RIF resistance indeterminate"]
N --> CE2["Further clinical evaluation<br/>CXR, culture, histopathology,<br/>cytopathology"]
D --> F2["First-line drugs"]
R --> S["Second-line drugs"]
E --> RX["Repeat Xpert"]
Adapted from BD-NTP 2021 section 4.5 diagnostic algorithm [p. 21]
| Test | Key points |
|---|---|
| Xpert MTB/RIF | Detects MTB and rifampicin resistance (rpoB) in about 2 hours. Also for extra-pulmonary samples: CSF, pleural, pericardial, ascitic and synovial fluid, FNAC, tissue, pus. Not blood, urine or stool |
| Culture | Gold standard. Solid 2–8 weeks; liquid (MGIT) up to 14 days. Used to monitor DR-TB treatment |
| Line probe assay | Resistance genes: rpoB (R), katG and inhA (H), gyrA/gyrB (fluoroquinolones). Second-line LPA for every RR-TB |
| Chest X-ray | Sensitive screening tool, but no shadow is specific. Can support a clinical diagnosis |
| Tuberculin skin test | Shows infection, not disease. Used for latent TB and as an aid in children. False negatives with HIV, malnutrition, miliary TB |
Adapted from BD-NTP 2021 section 4.3 [p. 18–20]
Extra-pulmonary TB (15–20% of cases)
| Site | Diagnosis |
|---|---|
| Lymph node (cervical commonest) | Firm, discrete, then matted and fluctuant, cold abscess and sinus. FNAC (smear, Xpert, culture) or biopsy |
| Miliary | CXR: uniform millet-seed shadows. Choroidal tubercles, hepatosplenomegaly. Bone marrow, liver biopsy or BAL |
| Pleural effusion | Straw-coloured, lymphocytic exudate (protein >30 g/L). AFB rarely seen. Pleural biopsy (yield about 75%) |
| Abdominal | Ileocaecal commonest. Ascites is a lymphocytic exudate; peritoneal biopsy (laparoscopic) is definitive |
| Spine (Pott's) | Lower thoracic (T10) and upper lumbar. Starts in the disc: disc space narrows (malignancy spares the disc). Cold or psoas abscess, gibbus |
| Genito-urinary | Sterile pyuria. Three early-morning urine cultures diagnose about 90% |
Adapted from BD-NTP 2021 section 4.7 [p. 22–25]
Treatment of drug-susceptible TB
| Patient | Intensive phase (daily) | Continuation phase (daily) |
|---|---|---|
| New: bacteriologically positive or negative pulmonary, extra-pulmonary, TB/HIV | 2 HRZE | 4 HR |
| Previously treated, H and R sensitive | 2 HRZE | 4 HR |
| Previously treated, clinically diagnosed pulmonary | 6 HRZE | |
| Complicated extra-pulmonary: meningitis, neurological, bone, non-resolving lymph node | 12 HRZE-Lfx | |
| R-susceptible, H-resistant or unknown (bacteriologically confirmed) | 6 (H)REZ-Lfx |
Adapted from BD-NTP 2021 standardised regimen table [p. 28]
| Weight (kg) | 4FDC daily, first 2 months | 2FDC daily, next 4 months | Hr-TB: 4FDC + Lfx 250 mg, 6 months |
|---|---|---|---|
| 30–37 | 2 | 2 | 2 + 2 |
| 38–54 | 3 | 3 | 3 + 3 |
| 55–70 | 4 | 4 | 4 + 4 |
| >70 | 5 | 5 | 5 + 5 |
4FDC = H 75 + R 150 + Z 400 + E 275 mg. 2FDC = H 75 + R 150 mg. Adapted from BD-NTP 2021 sections 5.6.2–5.7 [p. 29–30]
Rules for the regimen [p. 29–30]
- Intensive phase = 60 doses, never extended. Continuation phase = 120 doses.
- Re-dose if the patient moves to a new weight band.
- FDCs are preferred over separate drugs.
Extra-pulmonary TB
- Same 6-month regimen for most sites. Severe forms may get up to 12 months (2HRZE + up to 10HR), decided at 6 months. [p. 31]
- Lymph node not improving at 6 months: extend the continuation phase up to 10 months and test for drug resistance. [p. 31]
- TB meningitis: 12 months. Bone and spinal TB: 2HRZE / 10HR. Surgery for Pott's disease only with a neurological deficit, instability or no response. [p. 31–32]
Corticosteroids: TB meningitis and pericarditis [p. 31]
- Prednisolone 0.5–1 mg/kg/day (up to 2 mg/kg if severely ill) for 4 weeks, then taper by 2.5–5 mg a week over 4–8 weeks.
- Or dexamethasone 0.1–0.2 mg/kg/day for 2–4 weeks, then taper. About 12 weeks in total.
Monitoring
| When | Smear negative | Smear positive |
|---|---|---|
| End of month 2 | Start continuation phase | Xpert: R sensitive, start continuation phase. R resistant, treatment failure: start DR-TB treatment |
| End of month 5 | Continue | Treatment failure; test for resistance |
| End of month 6 | Cured |
Adapted from BD-NTP 2021 section 5.7.1 [p. 31]
| Outcome | Definition |
|---|---|
| Cured | Bacteriologically confirmed pulmonary TB, full course, smear negative at month 5 and at the end |
| Treatment completed | Full course, but no bacteriological proof of cure |
| Treatment failure | Regimen stopped or permanently changed, e.g. bacteriological reversion |
| Lost to follow-up | Didn't start, or interrupted for 2 consecutive months or more |
| Treatment success | Cured + completed |
Adapted from BD-NTP 2021 section 5.11 [p. 33]
Special situations
| Situation | Management |
|---|---|
| Pregnancy | Full standard course. Pyridoxine 10 mg/day. Vitamin K to the mother (10 mg/day for 15 days before delivery) and 1 mg IM to the newborn. Avoid levofloxacin: use 6 months of 4FDC instead |
| Breastfeeding | Full course; all drugs are compatible. Pyridoxine for the mother; isoniazid prophylaxis for the baby |
| Newborn of a smear-positive mother | Don't separate. Baby ill: full treatment. Baby well: 3 months of RH, then Mantoux: negative, stop and give BCG; positive, look for active TB |
| Contraception | Rifampicin reduces the pill's effect: use injectable, barrier or IUD (or a 50 µg oestrogen pill) |
| Chronic liver disease | No pyrazinamide: 2HRE / 7HR (9 months) |
| Acute viral hepatitis | Defer treatment until it resolves. Unstable or persistent hepatitis: 8 months of HRE, no pyrazinamide |
| Renal failure (CKD 4–5) | Standard regimen; H and R unchanged. Z 25 mg/kg and E 15 mg/kg three times a week. Pyridoxine |
| Diabetes | Standard regimen; tight glucose control, preferably insulin |
Adapted from BD-NTP 2021 sections 6.1–6.6 [p. 35–37]
Drug-induced hepatitis
- Pyrazinamide is the most hepatotoxic, then isoniazid, then rifampicin. Exclude other causes first. [p. 36]
- Enzymes <5 × normal, no symptoms: continue, with weekly LFTs. >5 × normal: stop all anti-TB drugs. [p. 39]
- Restart once LFTs settle: first the least hepatotoxic (ethambutol and a fluoroquinolone), then add one drug a week, R, then H, then Z, checking LFTs each week. Severe jaundice: avoid R and Z altogether. [p. 36, 39]
| Drug causing hepatitis | Alternative regimen |
|---|---|
| Pyrazinamide | 2HRE / 7HR, or 9HRE |
| Isoniazid | 9 RZE |
| Rifampicin | 9 Lfx-HZE |
| Pyrazinamide and rifampicin | 10 Lfx-HE |
Adapted from BD-NTP 2021 section 6.4.3 [p. 36]
Other serious reactions [p. 39–40]
- Moderate to severe rash: stop all drugs. Reintroduce one at a time in the order H, R, Z, fluoroquinolone, E. Never reintroduce a drug that caused Stevens–Johnson syndrome or anaphylaxis.
- Ethambutol: loss of red–green colour vision comes first. Stop it permanently.
- Rifampicin: shock, purpura, acute renal failure or haemolysis. Stop and never use again.
- Fluoroquinolones: QT prolongation, worse with moxifloxacin than levofloxacin.
Children
- Symptoms: cough >2 weeks despite antibiotics, fever >2 weeks, weight loss or no weight gain over 3 months, or reduced playfulness. Any one of these plus contact with TB means presumptive TB. [p. 42]
- Risk of disease after infection is highest under 1 year: 30–40% pulmonary and 10–20% disseminated or meningitis. [p. 42]
- Same regimen, 2HRZE / 4HR, using dispersible paediatric FDCs: HRZ 50/75/150 mg plus separate ethambutol 100 mg. Severe forms (meningitis, miliary, osteomyelitis, pericarditis): 9–12 months. [p. 44–45]
- Admit for respiratory distress, severe extra-pulmonary TB or severe drug reactions. [p. 44]
- Prednisolone 2 mg/kg/day for 4 weeks (up to 4 mg/kg, max 60 mg, if seriously ill) for meningitis, pericarditis or airway compression. [p. 46]
- Preventive therapy: child under 5 in contact with a bacteriologically confirmed case, once active TB is excluded: isoniazid 10 mg/kg daily for 6 months, whatever the BCG status. [p. 46]
| Weight | HRZ (50/75/150) | E (100 mg) | HR (50/75), continuation |
|---|---|---|---|
| 4–7 kg | 1 | 1 | 1 |
| 8–11 kg | 2 | 2 | 2 |
| 12–15 kg | 3 | 3 | 3 |
| 16–24 kg | 4 | 4 | 4 |
| ≥25 kg | Adult doses |
Adapted from BD-NTP 2021 section 8.6.1 [p. 45]
Drug-resistant TB
Who gets drug susceptibility testing (if it can't be offered to everyone): all previously treated patients, non-converters at month 2, symptomatic contacts of DR-TB, people with HIV, and patients deteriorating on first-line treatment. Every RR-TB gets a second-line LPA. [p. 48]
6 (H)REZ-Lfx. If later tests show isoniazid susceptibility, a new patient stops levofloxacin and completes 2HRZE/4HR. [p. 49]
Eligible: no resistance or more than 1 month's prior exposure to its drugs (except H), not extensive or severe extra-pulmonary disease, not pregnant, age ≥6 years.
| Phase | Drugs |
|---|---|
| Intensive, 4–6 months | Bdq (6 months) + Lfx + Cfz + Eto + E + high-dose H + Z |
| Continuation, 5 months | Lfx + Cfz + Z + E |
Bedaquiline: daily for 2 weeks, then three times a week for 22 weeks. The intensive phase is extended (max 6 months) only if still positive at month 4. [p. 49–50]
For anyone not eligible for the shorter regimen, including fluoroquinolone resistance.
| Fluoroquinolone | Regimen |
|---|---|
| Susceptible | 6 (Bdq-Lzd-Lfx-Cfz-Z) / 14 (Lzd-Lfx-Cfz-Z) |
| Resistant | 6 (Bdq-Dlm-Lzd-Cfz-Z-Cs) / 14 (Lzd-Cfz-Z-Cs) |
| Group | Drugs | Use |
|---|---|---|
| A | Levofloxacin or moxifloxacin, bedaquiline, linezolid | All three |
| B | Clofazimine, cycloserine or terizidone | One or both |
| C | Ethambutol, delamanid, pyrazinamide, imipenem or meropenem, amikacin, ethionamide, PAS | To complete the regimen |
Kanamycin and capreomycin are no longer used. BPaL (bedaquiline, pretomanid, linezolid for 6–9 months) only under operational research. [p. 50–51]
Latent TB and preventive treatment
Priority groups: PLHIV, and household contacts who are under 5 or 60 and over, diabetic, on dialysis, on anti-TNF treatment, transplant candidates, or have silicosis. Always exclude active TB first (symptoms, and CXR if needed). TST or IGRA can be used; neither separates latent from active TB. [p. 60–61]
| Regimen | Who | Dose |
|---|---|---|
| 3HP | Over 15 | Isoniazid 300 mg + rifapentine 300 mg, once weekly for 12 weeks |
| 3RH | Under 15 | Rifampicin + isoniazid daily for 3 months, by weight band |
| 6H | Adults with HIV | Isoniazid 300 mg daily for 6 months |
Adapted from BD-NTP 2021 section 12.4 [p. 62]
- Contacts of MDR-TB: no preventive treatment in Bangladesh; observe for at least 2 years. [p. 46, 62]
- PLHIV: start TPT the same day as ART if eligible. Don't give it with active TB, TB symptoms, an abnormal CXR, or TB treated in the past 3 years. [p. 65]
Clinical pearls
- New patient = less than 1 month of previous treatment. Lost to follow-up = 2 months' interruption.
- 2HRZE/4HR, 60 + 120 doses. 12 months for meningitis and bone TB.
- Sputum at months 2, 5 and 6. Positive at month 5 = failure.
- Chronic liver disease: no Z, 2HRE/7HR.
- Ethambutol: red–green colour vision first. Rifampicin: orange body fluids, enzyme induction (the pill, warfarin, DOACs, sulfonylureas).
- XDR = MDR + fluoroquinolone + bedaquiline or linezolid.
Classes and levels of evidence
NTP Bangladesh 2021 (6th ed) is a national programme guideline. It gives standard regimens and operational instructions without grading them by class or level of evidence, so citations on this page give only the page number in the original document. Where it follows WHO guidance, the strength of the WHO recommendation isn't restated.